Duarte Ira 4

What Happened

• Ira Duarte, Chief Financial Officer of Heron Therapeutics (HRTX), reported the exercise/conversion of restricted stock units into common stock on 2026-01-31. The filing shows 11,695 shares acquired (conversion) and the same 11,695 shares disposed at $0.00 (derivative).
• No cash proceeds are reported — the conversion (code M) and simultaneous disposition at $0.00 is consistent with settlement/withholding of vested RSUs rather than an open-market sale.

Key Details

• Transaction date: January 31, 2026. Filing date: February 3, 2026 (timely).
• Acquired: 11,695 shares (exercise/conversion of derivative; price N/A). Disposed: 11,695 shares @ $0.00 (derivative).
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes from the filing:
  • F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
  • F2: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).
• No 10b5-1 plan or late filing indicated in the report.

Context

• This report reflects conversion/settlement of RSUs, not a market sale or cash purchase. The reported disposal at $0.00 typically indicates shares were withheld or surrendered to satisfy tax or other obligations associated with vesting.
• Such routine RSU settlements are common for compensation and do not by themselves indicate a change in insider sentiment about the company.